The Worldwide Specialty Pharmaceuticals Industry is Expected to Reach $352+ Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Specialty Pharmaceuticals Market Research Report by Type, by Product, by Distribution Channel, by Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Specialty Pharmaceuticals Market size was estimated at USD 34.09 billion in 2020, is expected to reach USD 47.47 billion in 2021, and is projected to grow at a CAGR of 39.63% to reach USD 352.89 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Specialty Pharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Specialty Pharmaceuticals Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Specialty Pharmaceuticals Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Specialty Pharmaceuticals Market?

4. What is the competitive strategic window for opportunities in the Global Specialty Pharmaceuticals Market?

5. What are the technology trends and regulatory frameworks in the Global Specialty Pharmaceuticals Market?

6. What is the market share of the leading vendors in the Global Specialty Pharmaceuticals Market?

7. What modes and strategic moves are considered suitable for entering the Global Specialty Pharmaceuticals Market?

Market Dynamics

Drivers

• Increasing demand for specialty drugs to treat complex or serious chronic conditions
• Increased reimbursement through the medical benefit, and pharmacy benefit
• Specialty pharmacy providers collaborating with pharma/biotech manufacturers, payers, MCOs and patients
• Attractive prospects for biopharmaceutical companies from both business and medical innovation perspective

Restraints

• Cost sharing discourages the use leading to adverse health outcomes
• Growth in premium costs

Opportunities

• Retailers involvements in specialty market and several chains operate their own specialty pharmacy divisions
• Stimulated diagnostic research
• Vendors offering compliance programs, reimbursement assistance programs and distribution channels
• Growth of enhanced information technologies in the specialty sector
• Value-added programs targeting physicians, nurses, patients and caregivers

Challenges

• Less focus on development of low-cost generic equivalents of specialty drugs

Companies Mentioned

• Accredo Health Group, Inc.
• Avella Specialty Pharmacy, Inc.
• CIGNA Pharmacy Management
• CVS Health Corporation
• Diplomat Pharmacy, Inc.
• Endo Pharmaceuticals Inc.
• ENESI
• Humana Pharmacy, Inc.
• Hyphens Pharma Pte Ltd.
• Kroger Specialty Pharmacy, Inc.
• McKesson Corporation
• Midatech Pharma PLC
• UnitedHealth Group Incorporated
• US WorldMeds, LLC
• Walgreens Boots Alliance, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/vwwxlz

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900